Innate Pharma S.A.

Hello and thank you for standing by. My name is Regina and I will be your conference operator today. At this time, I would like to welcome everyone to the Innate Pharma Publication of Revenue for third quarter 2022 conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you'd like to ask a question during this time, simply press star then the number one on your telephone keypad. If you would like to withdraw your question, press star 1 again. I would now like to turn the conference over to Henry Wheeler, Head of Investor Relations. Please go ahead.

Thank you. Good morning, good afternoon, and welcome everyone. This morning, Enate issued a press release providing a business update for our Q3 2022 results. We look forward to highlighting the progress made during the quarter, as well as addressing future goals and milestones. The press release and today's presentation are both available on the IR section of the website. On slide two, before we start, I'd like to remind you that we will make forward-looking statements regarding the financial outlook in addition to regulatory and product plan developments. These statements are subject to risk and uncertainties that may cause actual results to differ from those forecasted. On slide three, on today's call, you'll see we will be joined by Monda Majubi, our Chief Executive Officer, who will then hand over to Joyce and Cara Connell, EVP and Chief Medical Officer, and then Yanis Morel, EVP of Business Development and Product Portfolio Strategy. We will also have our CFO, Frederick Lombard, on the line for Q&A. Monda, I'll now hand the call over to you.

Thank you, Henry. Good morning. Good afternoon, everyone, and thank you for joining our call today. Please move to slide four, and let me start by reminding you our strategies. Our strategy centers around three key priorities where we look to drive value from our early R&D efforts through later stage partnerships. Well, it makes sense to do so. Firstly, we look to create near-term value driven by our lead proprietary product candidate, Lakutamab, which is in development for TCN Informa with readouts in CTCL happening in the second half of this year. and two trials in the larger indication of peripheral T cell lymphoma underway. Second, we continue to shoot our pipeline and create longer-term value by leveraging our antibody engineering capabilities to develop innovative molecules with a primary focus on our multi-specific NK cell engager proprietary platform called NK. Sanofi has the most advanced NK in the clinic and has selected another candidate. And we are nearing the clinic with the others, notably with our CD20-targeting tetraspecific encode called APH6501. Last but not least, we are building a strong and sustainable foundation for our business, leveraging various partnerships across industry and academia. Here, our AstraZeneca partnership with Monolizumab, which is continuing in Lancaster. And our focus remains to leverage the value of our products as much as possible. We want to ensure that if we can gain valuable competencies via a partner agreement, we will consider that in our development plans for the products. This will further validate our science and offer capital that we can reinvest to advance our early portfolio. Before I hand over to Joyce, please move to slide five. On slide five is an overview of our pipeline, which shows how we continue to translate our size into a robust portfolio of proprietary and partnered assets. It also illustrates how we are executing against our strategy with our lead proprietary asset, like Hitamart, supported by partnered and earlier stage products, in particular from our NK-Cell Engager Unket platform. We anticipate a number of potential clinical readouts and catalysts in the upcoming couple of years as our R&D engine looks to leverage our scientific know-how to create a sustainable business. I would like now to pass the call over to Jason, who will review the progress made with our portfolio, starting with lacudamab, our most advanced proprietary asset. Jason, over to you.